Illinois Municipal Retirement Fund Buys 1,130 Shares of Eli Lilly and Company $LLY

Illinois Municipal Retirement Fund lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,175 shares of the company’s stock after purchasing an additional 1,130 shares during the quarter. Eli Lilly and Company accounts for approximately 0.7% of Illinois Municipal Retirement Fund’s portfolio, making the stock its 14th largest holding. Illinois Municipal Retirement Fund’s holdings in Eli Lilly and Company were worth $66,156,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Coastal Bridge Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $2,959,000. Birinyi Associates Inc. raised its position in shares of Eli Lilly and Company by 32.6% during the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after purchasing an additional 359 shares during the last quarter. Mosaic Family Wealth Partners LLC lifted its stake in Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after buying an additional 1,430 shares in the last quarter. Heritage Investors Management Corp lifted its stake in Eli Lilly and Company by 6.5% in the 3rd quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock valued at $13,624,000 after buying an additional 718 shares in the last quarter. Finally, Capital Investment Advisors LLC boosted its holdings in Eli Lilly and Company by 51.3% in the 3rd quarter. Capital Investment Advisors LLC now owns 44,851 shares of the company’s stock worth $51,896,000 after buying an additional 15,214 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. Morgan Stanley boosted their price objective on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a research report on Monday. Bank of America restated a “buy” rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. UBS Group lifted their price target on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, Argus boosted their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo met the primary endpoint in a Phase 3 trial for obstructive sleep apnea, reducing breathing interruptions by up to an average of 44%. Lilly plans to seek FDA approval for the additional use by year-end, which could broaden the pill’s commercial opportunity beyond weight loss. Reuters article
• Positive Sentiment: Jefferies raised its price target to $1,700 and maintained a Buy rating, signaling continued analyst confidence in Lilly’s prospects. Jefferies price target
• Positive Sentiment: Lilly’s agreement with Hims & Hers and a similar arrangement with LifeMD expands digital access to its branded obesity medicines, including Zepbound and Foundayo. Hims’ share-price decline following its own disappointing results appears company-specific; coverage reported Lilly holding steady. Yahoo Finance article
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden, potentially permanent vision loss. The class-wide warning could raise safety concerns for patients and investors, though the condition is rare. CNBC article

Eli Lilly and Company Stock Performance

LLY opened at $1,432.60 on Wednesday. The firm has a market capitalization of $1.35 trillion, a PE ratio of 46.50, a PEG ratio of 1.69 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00. The firm’s 50-day moving average price is $1,225.57 and its 200 day moving average price is $1,104.56. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $7.02 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 22.46%.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.